Gilead Sciences ( GILD) reported a fourth-quarter loss of $22.9 million, or 24 cents a share, excluding a $154.5 million gain from the sale of its cancer business, compared with a loss of $18.4 million, or 39 cents a share, a year ago. Wall Street had been expecting a loss of 29 cents a share, according to Thomson Financial/First Call.

Revenue for the quarter rose 42% to $74.3 million from $52.5 million in the year ago quarter.

The biotech company also reiterated its goal of becoming profitable on a full year basis in 2002. According to First Call, analysts are expecting a 5-cent loss for the full year.

Shares of Gilead closed at $65.42 Thursday before the announcement.

If you liked this article you might like

Stocks to Watch: Ann Taylor Climbs, Electronics Sellers Drop

Stocks to Watch: Ann Taylor Climbs, Electronics Sellers Drop

Tough Month, Better Quarter for Retailers

Tough Month, Better Quarter for Retailers

AON Plunges on Accounting Issues, Earnings

AON Plunges on Accounting Issues, Earnings

Stocks to Watch: TiVo Climbs on Guidance, Cross Country Plunges

Stocks to Watch: TiVo Climbs on Guidance, Cross Country Plunges

Polo Posts Lower First-Quarter Results

Polo Posts Lower First-Quarter Results